PHAS PhaseBio Pharmaceuticals, Inc.

9.870.00 (+0.00%)
15 minute delayed price: 9:53:30 AM

Quote

Previous Close
$9.87
Day Range
$9.85-$10.14
52 Week Range
$2.55-$16.65
Volume
23,595
Avg Volume
331,868
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$277.20M
Enterprise Value (EV)
$243.59M
PE Ratio
-
EV/EBITDA
-10.32
Price/Sales
-
Price/Book
5.44
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$23.61M
EPS, ttm
-$1.15
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/27/2019 (95 days)
Debt to Equity
15%
Debt
$27.44M
Cash
$61.05M
Net Debt
-

Performance

Beta
1.75
200 Day Moving Avg
$6.17
50 Day Moving Avg
$11.23
52 Week Change
97.40%
YTD Change
214.83%
1 Month Change
-22.77%
3 Month Change
218.39%
6 Month Change
221.50%
1 Year Change
97.40%
2 Year Change
166.80%
5 Year Change
166.80%

Share Count

Shares Outstanding
28.1M
Float
13.3M
Restricted Shares
14.7M
Restricted Shares, %
52.47%

PhaseBio Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Major

CEO: Jonathan P. Mow

Website: http://www.phasebio.com

Description: PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Employees: 24